The estimated Net Worth of Alexander A Fitzpatrick is at least 3.03 千$ dollars as of 20 December 2021. Mr. Fitzpatrick owns over 25,000 units of Evofem Biosciences Inc stock worth over 3,028$ and over the last 7 years he sold EVFM stock worth over 0$. In addition, he makes 0$ as Executive Vice President、 General Counsel、 Secretary at Evofem Biosciences Inc.
Alexander has made over 4 trades of the Evofem Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of EVFM stock worth 9,750$ on 20 December 2021.
The largest trade he's ever made was buying 25,000 units of Evofem Biosciences Inc stock on 20 December 2021 worth over 9,750$. On average, Alexander trades about 2,045 units every 51 days since 2018. As of 20 December 2021 he still owns at least 336,422 units of Evofem Biosciences Inc stock.
You can see the complete history of Mr. Fitzpatrick stock trades at the bottom of the page.
Alexander A. Fitzpatrick Esq., J.D. serves as Executive Vice President, General Counsel, Secretary of the Company. Mr. Fitzpatrick is responsible for our corporate governance, legal, corporate development, intellectual property and risk management functions. Prior to joining Evofem, Mr. Fitzpatrick served as Chief Legal Officer of Kyriba Corporation from 2014 to 2015 and Senior Vice President, General Counsel, Compliance Officer and Secretary of Verenium Corporation, a publicly traded biotechnology company from 2010 to 2014. Prior to that, Mr. Fitzpatrick served as Senior Vice President, General Counsel and Secretary of Kintera, Inc., a publicly traded technology company. Following the sale of Kintera, Mr. Fitzpatrick continued to serve in a similar position for a major division of Blackbaud, Inc. Prior to that, as a member of the business, corporate and technology departments with the law firms Cooley LLP and Latham & Watkins LLP in San Diego, and Rogers & Wells LLP (now Clifford Chance) in London, Mr. Fitzpatrick represented pharmaceutical and other technology companies, investment banks and venture capitalists in a variety of transactions including numerous collaborations, mergers and acquisitions, intellectual property matters, licensing and financing activity. Mr. Fitzpatrick received a B.S. in mathematics from Georgetown University and a J.D. from the University of California, Berkeley.
Alexander Fitzpatrick is 53, he's been the Executive Vice President、 General Counsel、 Secretary of Evofem Biosciences Inc since 2018. There are 8 older and 6 younger executives at Evofem Biosciences Inc. The oldest executive at Evofem Biosciences Inc is Gillian Greer, 75, who is the Independent Director.
Alexander's mailing address filed with the SEC is C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA, 92130.
Over the last 7 years, insiders at Evofem Biosciences Inc have traded over 32,368,585$ worth of Evofem Biosciences Inc stock and bought 12,978,479 units worth 54,857,186$ . The most active insiders traders include Research Corp Acacia、Fund Solutions Ltd Link、Biopharma, Inc. Pdl. On average, Evofem Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of 5,281$. The most recent stock trade was executed by Yan Zhang on 12 January 2024, trading 104 units of EVFM stock currently worth 4$.
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.
Evofem Biosciences Inc executives and other stock owners filed with the SEC include: